Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.

Abstract:

BACKGROUND:The prognostic value of molecular markers in renal cell carcinoma has been investigated in several studies. Although their value is still not confirmed, various proteins are important. We describe the effect on long-term survival of the status of the von Hippel-Lindau (VHL) hypoxia-inducible factor 1-α (HIF1-α) signaling pathway as well as associated mitogen-activated protein kinase (extracellular signal-regulated kinase [ERK]1/2 and ERK5). PATIENTS AND METHODS:A prospective, longitudinal cohort study was conducted with 50 patients diagnosed with clear-cell renal cell carcinoma to analyze VHL mutations and hypermethylation as well as VHL, HIF1-α, vascular endothelial growth factor (VEGF), ERK1/2, and ERK5 protein expression. Overall survival (OS), disease-specific survival (DSS), and progression- or recurrence-free survival (PFS) were analyzed using the Kaplan-Meier method. Mantel-Haenszel was used for comparisons, and Cox proportional risk models were also constructed. RESULTS:Follow-up was 66.9 months. There were 23 (46.0%) deaths, of which 17 (73.9%) were caused by the tumor. Mean periods were 85.6 months for OS and 94.3 months for DSS. A total of 22 (44.0%) patients showed progression (PFS, 78.1 months). VHL expression (P = .045) and > 10% of HIF1-α expression (P = .034) were associated with greater OS. DSS was greater in patients without VHL methylation (P = .012), with > 10% HIF1-α expression (P = .037), or with ERK5 protein underexpression. Greater PFS was associated with absence of VHL methylation (P = .045), presence of VHL expression (P < .0001), HIF1-α expression > 10% (P = .04), and ERK5 protein underexpression (P = .011). The presence of VHL mutation and/or methylation and VEGF expression had no prognostic value. Fuhrman nuclear grade and Tumor, Node, Metastases (TNM) stage were the only variables that remained in the Cox model. CONCLUSION:The HIF1-α and ERK5 pathway has prognostic value. Patients with no VHL or HIF1-α expression and ERK5 overexpression had a worse course of disease. VHL or VEGF status had no prognostic value. Only TNM stage and Fuhrman nuclear grade remained in the Cox model and, therefore, are still essential in prognostic biomarker panels.

journal_name

Clin Genitourin Cancer

authors

Salinas-Sánchez AS,Serrano-Oviedo L,Nam-Cha SY,Roche-Losada O,Sánchez-Prieto R,Giménez-Bachs JM

doi

10.1016/j.clgc.2017.05.016

subject

Has Abstract

pub_date

2017-12-01 00:00:00

pages

e923-e933

issue

6

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(17)30153-2

journal_volume

15

pub_type

杂志文章
  • Evaluation of Gleason Grade Group 5 in a Contemporary Prostate Cancer Grading System and Literature Review.

    abstract:INTRODUCTION:The aim of this study was to validate contemporary grading systems, in particular, the Gleason grade group (GGG) 5. PATIENTS AND METHODS:We retrospectively reviewed the clinicopathologic data of 176 patients who underwent radical prostatectomy and whose pathologic results were GGG 4 or 5. The endpoints we...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2020.08.001

    authors: Kamitani R,Matsumoto K,Kosaka T,Takeda T,Hashiguchi A,Tanaka N,Morita S,Mizuno R,Shinojima T,Asanuma H,Oya M

    更新日期:2020-08-07 00:00:00

  • Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.

    abstract:BACKGROUND:Cisplatin-based neoadjuvant chemotherapy (NAC) before cystectomy improves survival in muscle-invasive urothelial bladder cancer (MIBC). The use of NAC before chemoradiation (CRT) has been limited, as these patients are often elderly, frail, and ineligible for cisplatin. However, the role of NAC in fit, cispl...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.09.021

    authors: Jiang DM,Jiang H,Chung PWM,Zlotta AR,Fleshner NE,Bristow RG,Berlin A,Kulkarni GS,Alimohamed NS,Lo G,Sridhar SS

    更新日期:2019-02-01 00:00:00

  • Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.

    abstract:BACKGROUND:Piritrexim is reported to have a response rate of 38% in patients with chemotherapy-naive disease and 23% for second-line therapy after chemotherapy failure. We report the results of a multiinstitutional, open-label, 2-stage, phase II study that further evaluates oral piritrexim in patients with urothelial c...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CGC.2008.n.005

    authors: Lassiter LK,Tummala MK,Hussain MH,Stadler WM,Petrylak DP,Carducci MA

    更新日期:2008-03-01 00:00:00

  • Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.

    abstract:BACKGROUND:Renal dysfunction, poor performance status, and comorbidities may preclude frontline cisplatin-based chemotherapy in patients with advanced urothelial carcinoma (UC). The frequency of cisplatin-based chemotherapy administration in patients with advanced UC in community-based cancer centers is unknown. PATIE...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2011.11.005

    authors: Sonpavde G,Watson D,Tourtellott M,Cowey CL,Hellerstedt B,Hutson TE,Zhan F,Vogelzang NJ

    更新日期:2012-03-01 00:00:00

  • Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study.

    abstract:BACKGROUND:Nonurothelial carcinoma (UC) malignancies have traditionally been considered to have a more aggressive clinical course, and little is known about their response to neoadjuvant therapy. We examined the effect of neoadjuvant chemotherapy (NAC) on a large population of patients with bladder cancer (BCa) with di...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2020.01.007

    authors: Bandini M,Pederzoli F,Madison R,Briganti A,Ross JS,Niegisch G,Yu EY,Bamias A,Agarwal N,Sridhar SS,Rosenberg JE,Bellmunt J,Pal SK,Galsky MD,Lucianò R,Gallina A,Salonia A,Montorsi F,Ali SM,Chung JH,Necchi A

    更新日期:2020-10-01 00:00:00

  • Laparoscopic Partial Nephrectomy After Selective Embolization and Robot-Assisted Partial Nephrectomy: A Comparison of Short-Term Oncological and Functional Outcomes.

    abstract:BACKGROUND:Partial nephrectomy (PN) is the standard treatment for localized renal tumors. Laparoscopic PN (LPN) after selective embolization of tumor (LPNE) in a hybrid operating room has been developed to make LPN easier and safer. The aim of this study was to compare outcomes of LPNE and robot-assisted PN (RAPN). PA...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.07.005

    authors: Benoit M,Bouvier A,Panayotopoulos P,Culty T,Guillonneau B,Aube C,Azzouzi AR,Sebe P,Bigot P

    更新日期:2018-12-01 00:00:00

  • Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers.

    abstract:INTRODUCTION:There is scarce information regarding nivolumab treatment for metastatic renal cell carcinoma (mRCC) in patients with end-stage renal disease (ESRD). This study investigated the safety and efficacy of nivolumab in patients with mRCC and ESRD. MATERIALS AND METHODS:This 2-center retrospective study evaluat...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2019.04.004

    authors: Tachibana H,Kondo T,Ishihara H,Takagi T,Tanabe K

    更新日期:2019-08-01 00:00:00

  • Prognostic Value of Body Mass Index According to Histologic Subtype in Nonmetastatic Renal Cell Carcinoma: A Large Cohort Analysis.

    abstract:OBJECTIVE:The objective of our study was to assess the prognostic value of body mass index (BMI) according to histologic subtype in nonmetastatic renal cell carcinoma (RCC), based on a large multicenter experience. METHODS:A total of 2769 patients with nonmetastatic RCC at the time of surgery were enrolled from 5 Kore...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2015.04.012

    authors: Lee WK,Hong SK,Lee S,Kwak C,Oh JJ,Jeong CW,Kim YJ,Kang SH,Hong SH,Byun SS

    更新日期:2015-10-01 00:00:00

  • Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.

    abstract:BACKGROUND:Hyperglycemia and hypercholesterolemia are class effects of mammalian target of rapamycin inhibitors. The purpose of this study was to characterize safety and efficacy of patients with metastatic renal cell carcinoma (mRCC) treated with everolimus in RECORD-1 (REnal Cell cancer treatment with Oral RAD001 giv...

    journal_title:Clinical genitourinary cancer

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.clgc.2016.04.011

    authors: Bono P,Oudard S,Bodrogi I,Hutson TE,Escudier B,Machiels JP,Thompson JA,Figlin RA,Ravaud A,Basaran M,Porta C,Bracarda S,Brechenmacher T,Lin C,Voi M,Grunwald V,Motzer RJ

    更新日期:2016-10-01 00:00:00

  • Racial and Socioeconomic Disparities in Bladder Cancer Survival: Analysis of the California Cancer Registry.

    abstract:PURPOSE:To examine the California Cancer Registry (CCR) for bladder cancer survival disparities based on race, socioeconomic status (SES), and insurance in California patients. PATIENTS AND METHODS:The CCR was queried for bladder cancer cases in California from 1988 to 2012. The primary outcome was disease-specific su...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.05.008

    authors: Sung JM,Martin JW,Jefferson FA,Sidhom DA,Piranviseh K,Huang M,Nguyen N,Chang J,Ziogas A,Anton-Culver H,Youssef RF

    更新日期:2019-10-01 00:00:00

  • Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.

    abstract::Effective options are lacking for progressive castration-refractory prostate cancer (CRPC) after conventional chemotherapy. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor that is approved multinationally for renal cell carcinoma and gastrointestinal stromal tumors. A phase II trial was con...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CGC.2008.n.023

    authors: Sonpavde G,Hutson TE,Berry WR,Boehm KA,Asmar L

    更新日期:2008-09-01 00:00:00

  • Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.

    abstract:INTRODUCTION:Pembrolizumab has been approved in the United States (US) for the first-line treatment of patients with advanced or metastatic urothelial carcinoma, who are ineligible for cisplatin-containing chemotherapy and with tumors expressing programmed death-ligand 1 (PD-L1) (Combined Positive Score ≥ 10), or ineli...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2020.07.006

    authors: Hale O,Patterson K,Lai Y,Meng Y,Li H,Godwin JL,Homet Moreno B,Mamtani R

    更新日期:2020-07-16 00:00:00

  • Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands.

    abstract:BACKGROUND:The purpose of this study was to determine generic, cancer-specific, and prostate cancer-specific health-related quality of life (HRQoL), pain and changes over time in patients with metastatic castration-resistant prostate cancer (mCRPC) in daily practice. PATIENTS AND METHODS:PRO-CAPRI is an observational,...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.11.015

    authors: Kuppen MCP,Westgeest HM,van den Eertwegh AJM,Coenen JLLM,van Moorselaar RJA,van den Berg P,Geenen MM,Mehra N,Hendriks MP,Lampe MI,van de Luijtgaarden ACM,Peters FPJ,Roeleveld TA,Smilde TJ,de Wit R,van Oort IM,Gerritsen WR

    更新日期:2020-06-01 00:00:00

  • Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.

    abstract:BACKGROUND:Scatter factor, also known as hepatocyte growth factor (SF/HGF), is a polypeptide growth factor thought to be important in the growth and spread of prostatic carcinoma. PATIENTS AND METHODS:Scatter factor/HGF levels in pretreatment plasma samples from 171 men with metastatic hormone-refractory prostate canc...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2006.n.006

    authors: Humphrey PA,Halabi S,Picus J,Sanford B,Vogelzang NJ,Small EJ,Kantoff PW

    更新日期:2006-03-01 00:00:00

  • Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience.

    abstract:INTRODUCTION:Abiraterone improves survival in metastatic castration-resistant prostate cancer (mCRPC) but may result in the development or worsening of comorbid conditions. We assessed the course of these conditions in patients receiving abiraterone in clinical practice and compared outcomes with those in clinical tria...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.03.001

    authors: Tsao PA,Estes JP,Griggs JJ,Smith DC,Caram MEV

    更新日期:2019-06-01 00:00:00

  • Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.

    abstract:INTRODUCTION/BACKGROUND:Targeted therapy has become the mainstay of treatment for mRCC. The efficacy of this therapy in the older population is poorly understood. PATIENTS AND METHODS:Data from patients with mRCC treated with first-line anti-VEGF therapy were collected through the International mRCC Database Consortiu...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.02.009

    authors: Khambati HK,Choueiri TK,Kollmannsberger CK,North S,Bjarnason GA,Vaishampayan UN,Wood L,Knox JJ,Tan MH,MacKenzie MJ,Donskov F,Rini BI,Heng DY,International mRCC Database Consortium.

    更新日期:2014-10-01 00:00:00

  • Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors.

    abstract:BACKGROUND:We comprehensively tested contemporary incidence and mortality rates in patients with germ cell tumor of the testis (GCTT). MATERIALS AND METHODS:Within the Surveillance, Epidemiology, and End Results database (2004-2015), statistical analyses included estimated annual percentage changes, multivariable logi...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.06.003

    authors: Palumbo C,Mistretta FA,Mazzone E,Knipper S,Tian Z,Perrotte P,Antonelli A,Montorsi F,Shariat SF,Saad F,Simeone C,Briganti A,Lattouf JB,Karakiewicz PI

    更新日期:2019-10-01 00:00:00

  • Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?

    abstract:BACKGROUND:Abiraterone acetate (AA) increases overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel. However, survival time varies substantially between individuals. Our goal was to identify prognostic factors that better estimate OS. MATERIALS...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2017.01.019

    authors: Van Praet C,Rottey S,Van Hende F,Pelgrims G,Demey W,Van Aelst F,Wynendaele W,Gil T,Schatteman P,Filleul B,Schallier D,Machiels JP,Schrijvers D,Everaert E,D'Hondt L,Werbrouck P,Vermeij J,Mebis J,Clausse M,Rasschaert

    更新日期:2017-08-01 00:00:00

  • Nucleolin Staining May Aid in the Identification of Circulating Prostate Cancer Cells.

    abstract:INTRODUCTION:Circulating tumor cells (CTCs) have great potential as circulating biomarkers for solid malignancies. Currently available assays for CTC detection rely on epithelial markers with somewhat limited sensitivity and specificity. We found that the staining pattern of nucleolin, a common nucleolar protein in pro...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.12.004

    authors: Chalfin HJ,Verdone JE,van der Toom EE,Glavaris S,Gorin MA,Pienta KJ

    更新日期:2017-06-01 00:00:00

  • Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.

    abstract:BACKGROUND:Level 1 evidence has demonstrated increased overall survival with cisplatin-based neoadjuvant chemotherapy for patients with muscle-invasive urothelial cancer. Usage remains low, however, in part because neoadjuvant chemotherapy will not be effective for every patient. To identify the patients most likely to...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2016.03.006

    authors: O'Donnell PH,Alanee S,Stratton KL,Garcia-Grossman IR,Cao H,Ostrovnaya I,Plimack ER,Manschreck C,Ganshert C,Smith ND,Steinberg GD,Vijai J,Offit K,Stadler WM,Bajorin DF

    更新日期:2016-12-01 00:00:00

  • Positive surgical margins after nephron-sparing surgery for renal cell carcinoma: incidence, clinical impact, and management.

    abstract::Nephron-sparing surgery (NSS) for renal cell carcinoma (RCC) offers comparable oncologic results but a lower risk of chronic kidney disease when compared with radical nephrectomy; however it can result in positive surgical margins (PSMs) and consequently to a possible risk of oncologic failure. The aim of this review ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2012.09.010

    authors: Borghesi M,Brunocilla E,Schiavina R,Martorana G

    更新日期:2013-03-01 00:00:00

  • Effect of perioperative blood transfusion on mortality for major urologic malignancies.

    abstract:INTRODUCTION:Patients who undergo surgical treatment for malignancy often receive perioperative blood transfusion (PBT). We examined the association between PBT and mortality in patients who received surgical treatment of prostate, bladder, and kidney cancer. MATERIALS AND METHODS:Using the Surveillance, Epidemiology,...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.12.006

    authors: Soubra A,Zabell JR,Adejoro O,Konety BR

    更新日期:2015-06-01 00:00:00

  • Spontaneous intraperitoneal perforation of the bladder: a late complication of radiation therapy for prostate cancer.

    abstract::The spontaneous intraperitoneal rupture of the urinary bladder is an extremely rare and life-threatening event. Often, there are difficulties in establishing the diagnosis. A patient with spontaneous perforation of the urinary bladder, 17 years after successful treatment of an adenocarcinoma of the prostate by pelvic ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2007.n.006

    authors: Ketata S,Boulaire JL,Al-Ahdab N,Bargain A,Damamme A

    更新日期:2007-03-01 00:00:00

  • Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.

    abstract:BACKGROUND:Myalgia and arthralgia immune-related adverse events (irAEs) in patients treated with checkpoint inhibitors (CPIs) present a clinical challenge. We describe the clinical characteristics and treatment of myalgia and arthralgia irAEs in CPI-treated patients with genitourinary (GU) malignancies. PATIENTS AND M...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.01.021

    authors: Ornstein MC,Calabrese C,Wood LS,Kirchner E,Profusek P,Allman KD,Martin A,Kontzias A,Grivas P,Garcia JA,Calabrese LH,Rini BI

    更新日期:2019-06-01 00:00:00

  • Baseline serum 25-hydroxyvitamin d levels in men undergoing radical prostatectomy: is there an association with adverse pathologic features?

    abstract:INTRODUCTION/BACKGROUND:The purpose of this study was to evaluate the prevalence of vitamin D (VitD) deficiency in men undergoing radical prostatectomy and determine whether an association exists between preoperative VitD levels and adverse pathologic features. PATIENTS AND METHODS:Patients scheduled to undergo radica...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.02.004

    authors: Berg WT,Shapiro EY,Rothberg MB,Bergman A,Scarberry K,Wambi C,Patel T,Badani KK

    更新日期:2014-10-01 00:00:00

  • Histopathologic Characteristics of Upper Tract Urothelial Carcinoma With an Emphasis on Their Effect on Cancer Survival: A Single-Institute Experience With 305 Patients With Long-Term Follow-Up.

    abstract:INTRODUCTION:Tumor stage and grade represent the best established predictors for the prognosis of upper tract urothelial carcinoma (UTUC). However, controversies still exist regarding the role of tumor necrosis, location, and multifocality in the prognosis of UTUC. We share our experience with 305 patients, reporting o...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.04.017

    authors: Elawdy MM,Taha DE,Elbaset MA,Abouelkheir RT,Osman Y

    更新日期:2016-12-01 00:00:00

  • Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review.

    abstract::Nephrectomy is the reference-standard treatment for renal-cell carcinoma (RCC). For patients with unresectable disease, tumor may be shrunk by using chemotherapy, thereby permitting surgical resection, which can be curative. We provided neoadjuvant cabozantinib, the preferred tyrosine kinase inhibitor for advanced RCC...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2020.04.003

    authors: Roy AM,Briggler A,Tippit D,Dawson K,Verma R

    更新日期:2020-12-01 00:00:00

  • The R.E.N.A.L. nephrometric nomogram cannot accurately predict malignancy or aggressiveness of small renal masses amenable to partial nephrectomy.

    abstract:INTRODUCTION/BACKGROUND:The prediction of histology of SRM could be essential for their management. The RNN is a statistical tool designed to predict malignancy or high grading of enhancing renal masses. In this study we aimed to perform an external validation of the RNN in a cohort of patients who received a PN for SR...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2014.02.003

    authors: Antonelli A,Furlan M,Sandri M,Minervini A,Cindolo L,Parma P,Zaramella S,Porreca A,Vittori G,Samuelli A,Dente D,Berardinelli F,Raspollini MR,Serni S,Carini M,Terrone C,Schips L,Simeone C

    更新日期:2014-10-01 00:00:00

  • Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials.

    abstract:BACKGROUND:We characterized clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib who were long-term responders (LTRs), defined as patients having progression-free survival (PFS) > 18 months. PATIENTS AND METHODS:A retrospective analysis of data from 5714 patients with mRCC t...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2017.06.005

    authors: Tannir NM,Figlin RA,Gore ME,Michaelson MD,Motzer RJ,Porta C,Rini BI,Hoang C,Lin X,Escudier B

    更新日期:2017-06-20 00:00:00

  • Prognostic Significance of Preoperative Serum Lactate Dehydrogenase in Upper Urinary Tract Urothelial Carcinoma.

    abstract:BACKGROUND:Upper urinary tract urothelial carcinoma (UUTUC) is one of the uncommon malignancies lacking of prognostic indicators. Lactate dehydrogenase (LDH) has been demonstrated to correlate with clinical outcomes in human cancers. In this study, we aimed to evaluate the prognostic implication of the preoperative LDH...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.01.003

    authors: Zhang XK,Zhang ZL,Lu X,Yang P,Cai MY,Hu WM,Yun JP,Zhou FJ,Qian CN,Cao Y

    更新日期:2016-08-01 00:00:00